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Dopamine (DA) has been suggested to modulate functions of glial cells including microglial cells. To
reveal the regulatory role of DA in microglial function, in the present study, we investigated the effect of
DA on lipopolysaccharide (LPS)-induced nitric oxide (NO) production in murine microglial cell line BV-2.
Pretreatment with DA for 24 h concentration-dependently attenuated LPS-induced NO production in BV-
2 cells. The inhibitory effect of DA on LPS-induced NO production was not inhibited by SCH-23390 and
sulpiride, D1-like and D2-like DA receptor antagonists, respectively. In addition, pretreatment with
()-(6aR,12bR)-4,6,6a,7,8,12b-Hexahydro-7-methylindolo[4,3-a]phenanthridin (CY 208e243) and
bromocriptine, D1-like and D2-like DA receptor agonists, respectively, did not affect the LPS-induced NO
production. N-Acetylcysteine, which inhibits DA oxidation, completely inhibited the effect of DA.
Tyrosinase, which catalyzes the oxidation of DA to DA quionone (DAQ), accelerated the inhibitory effect
of DA on LPS-induced NO production. These results suggest that DA attenuates LPS-induced NO pro-
duction through the formation of DAQ in BV-2 cells.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nitiric oxide (NO), a bioactive free radical, is involved in various
physiological and pathological processes in many organ systems,
including the brain (1, 2). NO is enzymatically formed from arginine
by the enzyme NO synthase (NOS). This enzyme exists in 2 forms.
One is the constitutive form, which is present in neurons (nNOS)
and endothelial cells (eNOS) and is a calcium-dependent enzyme
(3, 4). The other is the inducible form (iNOS), which is expressed in
various cell types, including microglial cells, in response to a wide
variety of stimuli; and it is regulated mainly at the transcriptional
level and does not require calcium for its activity (5).
Microglial cells are the resident macrophage-like cells in the
central nervous system (CNS). They play critical roles in the im-
mune and inﬂammatory responses of the CNS (6). Microglial cells in: þ81 72 866 3146.
. Yoshioka).
rmacological Society.
. Production and hosting by Elsethe healthy brain do not express iNOS; but following ischemic,
traumatic, neurotoxic or inﬂammatory damage, they become acti-
vated to produce iNOS and to release a large amount of NO (7e10).
The excess production of NO causes neuronal apoptosis after acute
traumatic spinal cord injury, provokes delayed neuronal death
following acute injury in the striatum, and induces delayed
neurotoxicity following brain ischemia (11e13). Thus, the regula-
tion of NO production by microglial cells is important for the
maintenance of brain homeostasis and is vital for neuronal survival
following brain injury.
Dopamine (DA) is the predominant catecholamine neurotrans-
mitter in the mammalian brain and controls a variety of functions,
including locomotor activity, cognition, emotion, positive rein-
forcement, food intake, and endocrine regulation. These physio-
logical actions of DA are mainly produced through its interaction
with speciﬁc G protein-coupled receptors, which are currently
recognized as subfamilies of D1-like and D2-like receptors (14). On
the other hand, DA receptor-independent actions of DA have also
been demonstrated. DA readily oxidizes nonenzymatically to DA
quinone (DAQ; 15,16), and DAQ can modify cysteine residues ofvier B.V. This is an open access article under the CC BY-NC-ND license (http://
Y. Yoshioka et al. / Journal of Pharmacological Sciences 130 (2016) 51e5952certain proteins and modulate their function (17e19). DA is
released into the extracellular space via leaky DA synapses or non-
junctional DA terminal varicosities and is suggested to modulate
not only neuronal functions but also glial cell functions (20). In
addition, the release of DA has been shown to increase after brain
ischemia (21) and decrease after traumatic brain injury (22).
Therefore, it is important to reveal the regulatory role of DA in
microglial function in order to understand the pathophysiology of
these brain injuries.
In the present study, we investigated the effect of DA on lipo-
polysaccharide (LPS)-induced NO production in murine microglial
cell line BV-2. We ﬁrstly demonstrated that DA attenuated NO
production in microglial cells through formation of DAQ.
2. Materials and methods
2.1. Antibody and chemicals
Anti-inducible NO synthase (iNOS) polyclonal antibody was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). LPS
from Escherichia coli (strain O111:B4), DA hydrochloride, the DA D1-
like receptor antagonist SCH-23390, the DA D2-like receptor
antagonist sulpiride, N-acetyl-L-cysteine (NAC), ascorbic acid, nitro
blue tetrazolium (NBT), tyrosinase and mouse recombinant tumor
necrosis factor-a (TNF-a) were obtained from Sigma (St. Louis, MO,
USA). The DA D1-like receptor agonist ()-(6aR,12bR)-
4,6,6a,7,8,12b-Hexahydro-7-methylindolo[4,3-a]phenanthridin (CY
208-243) was purchased from Tocris Bioscience (Ellisville, MO,
USA). The DA D2-like receptor agonist bromocriptine mesylate,
ascorbic acid, hypoxanthine (HX), xanthine oxidase (XO), mouse
recombinant interferon-g (IFN-g) and all other chemicals were
purchased from Wako Pure Chemical (Osaka, Japan).
2.2. Cell culture and treatment with drugs
Cells of the clonal murine microglial cell line BV-2 were main-
tained in Dulbecco's modiﬁed Eagle's medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS/DMEM),
as described previously (Yoshioka et al., 2010). The cells were plated
at a density of 1  105/well in 24-well tissue culture plates for the
Griess assay or at 6  105 in 60 mm-diameter dishes for real-time
RT-PCR, Western blotting, and NBT/glycinate assay.
Primary cultures of mouse microglia were prepared from post-
natal day 0e2 C57BL/6 mice according to the method described by
Esen and Kielian (23) with some modiﬁcations. In brief, the cere-
brum was isolated, minced, and placed in ice-cold 0.25% trypsin-
EDTA solution (SigmaeAldrich, St. Louis, MO, USA). Cells were
dissociated for 5 min at 37 C with agitation every few minutes.
After mechanical and chemical dissociation, the population of
mixed glial cells was ﬁltered through a-100 mm cell strainer (BD
Falcon, Franklin Lakes, NJ, USA) and plated on 75-cm2 ﬂasks in FBS/
DMEM supplemented with 1% penicillin/streptomycin (Sigma-
eAldrich, St. Louis, MO, USA). Mixed glial cultures were maintained
in culture in a humidiﬁed incubator at 37 C and 5% CO2 for 14e20
days, and media were replenished every 3e4 days. Once the pri-
mary cultures reached conﬂuence, the microglial cells were iso-
lated from the astroglial cell bed by mechanical agitation on an
orbital shaker (200 rpm) for 1 h at 37 C. The purity of microglial
cultures was conﬁrmed with immunostaining for Iba1, and the
cultures were >95% pure. The microglial cells were plated in FBS/
DMEM supplemented with 1% penicillin/streptomycin at a density
of 2  105/well in 24-well tissue culture plates for the Griess assay.
The animal experiments were performed in accordance with the
guidelines of the Japanese Society for Pharmacology and were
approved by the Committee for the Ethical Use of ExperimentalAnimals at Setsunan University (approval ID: K12-14). All efforts
were made to minimize animal suffering, reduce the number of
animals used, and utilize alternatives to in vivo techniques.
The cells were incubated with 1e100 mM DA for 1e24 h. Then
the culture mediumwas aspirated and replaced with freshmedium
containing LPS or the combination of IFN-g and TNF-a. To assess the
effect of tyrosinase, the treatment of BV-2 cells with tyrosinase was
performed in the DMEM without tyrosine and phenol-red (tyro-
sine-free DMEM). All other experiments were performed using FBS/
DMEM. Surpiride, CY208-243 and bromocriptine were dissolved in
dimethyl sulfoxide and diluted in FBS/DMEM. SCH-23390, sulpir-
ide, NAC and ascorbic acid were added 1 h before exposure to DA.
2.3. Griess assay
For veriﬁcation of NO production, the level of nitrite, a stable
end product of NO metabolism, was measured in cell-free super-
natants by using the Griess reagent (1% sulfanilamide, 0.1% naph-
thylethylenediamine dihydrochloride, and 2.5% phosphoric acid),
as described previously (24). Brieﬂy, after LPS treatment, cell-free
supernatants were obtained and mixed with an equal volume of
the Griess reagent. The absorbance was measured at 570 nmwith a
microplate reader (Model 680, BIO-RAD, Hercules, CA, USA), and
nitrite concentrations were determined with reference to a cali-
bration curve prepared with sodium nitrite standards.
2.4. RT-PCR and real-time RT-PCR
Total RNA was isolated from cells by using a SV Total RNA
Isolation System (Promega, Madison,WI, USA). RNA (1 mg each) was
reverse transcribed with random primers (Invitrogen, Grand Island,
NY, USA) and M-MLV reverse transcriptase (Invitrogen).
The primer sequences for the RT-PCR analysis of dopamine re-
ceptor subtypeswere D1 (sense: 50-AACTGTATGGTGCCCTTCTGTGG-
30, antisense: 50-GCCCCGTTGTTGTTGATGCTTAC-30), D2 (sense: 50-
CACTCCGCCACTTCTTGACATACA-30, antisense: 50-AGCCCCATCCA-
CAGCCTCCTCT-30), D3 (sense: 50-GTCCTGCCCTCTCCTCTTTGGTTT-30,
antisense: 50-CATTTGTCCCGTGGCATCTGA-30), D4 (sense: 50-
TGCCCTCAACCCCATCATCTACAC-30, antisense: 50-TCCCAACCCC-
CAGCCTTCATAA-30) and D5 (sense: 50-GGGAGATCGCTGCTGCC
TATGTC-30, antisense: 50-ATTGGGGGTGAGTGGTGAGATTTT-30).
Thermal cycling conditions included 2 min at 55 C and 10 min at
95 C, followed by 40 cycles of 95 C for 15 s and 55 C for 1min. The
PCRproductwas subjected to electrophoresis on 2% agarose, stained
with ethidium bromide, and viewed under UV light.
Real-time PCRwas carried out by using SYBRGreen ﬂuorescence
according to the manufacturer's instructions (ABI Prism 7900-HT,
Applied Biosystems, Foster City, CA, USA). The Cp value of iNOS
(sense: 50-ACATCGACCCGTCCACAGTAT-30, antisense: 50-CAGAGG
GGTAGGCTTGTCTC-30, 177 bp) was normalized based on that of b-
actin (sense: 50-AGTGTGACGTTGACATCCGTA-30, antisense: 50-
GCCAGAGCAGTAATCTCCTTCT-30, 112 bp). A melting curve analysis
was carried out after ampliﬁcation to verify the accuracy of the
amplicon formation.
2.5. Western blot analysis
Toprepare cell lysates for immunodetectionof iNOS,we lysed BV-
2 cells in a buffer consisting of 50 mM TriseHCl (pH 7.4), 150 mM
sodium chloride, 1% Nonidet P-40 (NP-40), 0.5% sodium deoxy-
cholate, 0.1% sodiumdodecylsulfate (SDS),10 mgmL1 aprotinin, and
100 mMphenylmethylsulfonyl ﬂuoride (PMSF). The cell lysate (30 mg
protein) was blotted onto a polyvinylidene diﬂuoride membrane
after separation of the proteins by SDS-PAGE. The membrane was
stained with Ponceau S to conﬁrm equal loading and transfer
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saline (TBS) and blocked for 30 min with 1% non-fat dry milk/TBS/
0.1% Tween-20. It was next incubated for 2 h at room temperature
with the anti-iNOS polyclonal antibody (1:1000 dilution). Thereafter
the membrane was rinsed 5 times with TBS/0.1% Tween-20, and
subsequently incubated for 1 h with horseradish peroxidase-
conjugated anti-rabbit IgG polyclonal antibody (Cappel, West Ches-
ter, PA, USA). Signals were detected with a chemiluminescence
detection kit (NEN Life Science Products, Boston, MA, USA).
2.6. NBT/glycinate assay
For detection of protein-bound quinones (quinoprotein), the
NBT/glycinate assay was performed as described by Paz et al. (25)
with some modiﬁcation. Total cell lysates were prepared with
ice-cold buffer containing 10 mM sodium phosphate (pH 7.4),
138 mM sodium chloride, 2.7 mM potassium chloride, 100 mM
PMSF, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS. Each cell
lysate (400 mg protein/200 mL) was added to 1 mL of NBT reagent
(0.24 mM NBT in 2 M potassium glycinate, pH 10.0), and the
mixture was then incubated in the dark for 2 h on a shaker. The
absorbance of the blue-purple color developed in the reaction
mixture was measured at 530 nm.
2.7. Statistical evaluation
The results were expressed as the means ± s.e. obtained from 3
to 4 independent experiments. One-way ANOVA was used to testFig. 1. DA attenuated LPS-induced NO production by inhibiting the induction of iNOS in micr
24 h. The level of nitrite was then determined by performing the Griess assay. (BeF) BV-2 cell
10 mM DA for indicated times (C). Then the cells were treated with 0.1 mg mL1 LPS for 24
determined by performing the Griess assay, real-time RT-PCR and Western blotting, respect
The levels of iNOS mRNA (D) and protein (F) were expressed as relative to the maximum ex
from 3 to 4 independent experiments (AeD, F) and blots representative of 4 independent e
(Sheffe's test).for differences between group means. When appropriate, post hoc
multiple comparisons were performed to test for differences be-
tween experimental groups (Scheffe's test or Dunnett's test). When
the P value was less than 0.05, the difference was considered to be
signiﬁcant.3. Results
3.1. DA attenuated LPS-induced NO production and iNOS expression
in murine microglial BV-2 cells
We estimated LPS-induced NO production in BV-2 cells using
the Griess assay. Treatment of the cells with LPS for 24 h increased
NO production in a concentration-dependent manner (Fig. 1A). We
examined the effect of pretreatment of the cells with DA on the LPS-
induced NO production. Pretreatment of the cells with DA for 24 h
attenuated the LPS-induced NO production in a concentration-
dependent manner (Fig. 1B). DA at a concentration up to 100 mM
did not have any cytotoxicity towards BV-2 cells (data not shown).
The time-course of 10 mM DA pretreatment revealed that a mini-
mum of 9 h pretreatment was required to inhibit the LPS-induced
NO production (Fig. 1C). Next, we examined the effect of pretreat-
ment with DA for 24 h on the levels of iNOS mRNA and protein. The
pretreatment with DA inhibited the expression of iNOS mRNA and
protein induced by LPS in a concentration-dependent manner
(Fig. 1DeF). These results suggest that DA attenuated LPS-induced
NO production by inhibiting the induction of iNOS protein in BV-
2 cells.oglial BV-2 cells. (A) BV-2 cells were treated with LPS at the indicated concentrations for
s were treated with DA at the indicated concentrations for 24 h (B, D, E), or treated with
h. The levels of nitrite (B, C), iNOS mRNA (D), and iNOS protein (E) were subsequently
ively. Relative intensity of iNOS protein band was quantitated by using a densitometer.
pression level, which was arbitrarily set as 1.0. Results show the mean ± s.e. obtained
xperiments (E). **P < 0.01, signiﬁcantly different from values without DA pretreatment
Fig. 3. DA receptor-independent inhibition by DA of LPS-induced NO production in BV-
2 cells. (A) BV-2 cells were treated for 24 h with 10 mM DA in the absence or presence
of SCH-23390 (10, 30 mM) or sulpiride (10, 30 mM). Then the cells were treated with
0.1 mg mL1 LPS for 24 h. The nitrite levels were determined by performing the Griess
assay. (B) BV-2 cells were treated with CY 208-243 and/or bromocriptine at the indi-
cated concentrations for 24 h. Then the cells were treated with 0.1 mg mL1 LPS for
24 h. The nitrite levels were determined by performing the Griess assay. Results show
the mean ± s.e. obtained from 4 independent experiments. *P < 0.05, signiﬁcant dif-
ference between bracketed values (Sheffe's test).
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independent of DA receptor activation
We examined the expression of D1-like (D1 and D5) and D2-like
(D2, D3 and D4) DA receptors by RT-PCR in BV-2 cells and mouse
primary microglial cells, and conﬁrmed the expression of D1-like
and D2-like receptors in BV-2 (D2 and D5) and primary microglial
cells (D1 and D2, Fig. 2). Neither D3 nor D4 receptor mRNA was
detected in BV-2 and primary microglial cells. We investigated the
involvement of DA receptors in the attenuation of LPS-induced NO
production by DA. D1-like DA receptor antagonist SCH-23390 and
D2-like DA receptor antagonist sulpiride did not affect the attenu-
ation of LPS-induced NO production by 10 mM DA (Fig. 3A). In
addition, pretreatment with D1-like DA receptor agonist CY
208e243 and D2-like DA receptor agonist bromocriptine for 24 h
did not attenuate LPS-induced NO production (Fig. 3B). Pretreat-
ment with the combination of 10 mM CY 208-243 and 10 mM
bromocriptine also did not attenuate LPS-induced NO production.
These results suggest that the inhibition of LPS-induced NO pro-
duction by DA was independent of DA receptors.
3.3. DA attenuated LPS-induced NO production through the
formation of DAQ
We examined the effects of NAC and ascorbic acid on the
attenuation of LPS-induced NO production by DA to investigate the
involvement of ROS and DAQ in the effect of DA. The attenuation of
LPS-induced NO production by pretreatment with 10 mM DA was
completely inhibited by 10 mM NAC or 500 mM ascorbic acid
(Fig. 4A). On the other hand, pretreatment of the cells with the
combination of XO (1e30 mU/mL) and HX (50 mM), which gener-
ates superoxide anion, did not affect the LPS-induced NO produc-
tion (Fig. 4B), nor did that with hydrogen peroxide (10e100 mM,
Fig. 4C). These results suggest that the DAQ was involved in DA-
induced inhibition of NO production.
To assess the involvement of DAQ in the inhibitory effect of DA
on NO production, we examined the effect of tyrosinase, which
catalyzes the oxidation of DA to DAQ (26), on DA-induced attenu-
ation of LPS-induced NO production. To avoid the effect of ROS,Fig. 2. RNA expression of dopamine receptor subunits in BV-2 cells and mouse pri-
mary microglial cells. The mRNA expressions of D1-like and D2-like dopamine re-
ceptors in BV-2 cells and mouse primary microglial cells were examined by RT-PCR
analysis. Agarose gel electrophoresis of PCR ampliﬁed products of D1 (230 bp; lane 1
and 2), D2 (208 bp; lane 3 and 4), D3 (310 bp; lane 5 and 6), D4 (202 bp; lane 7 and 8),
and D5 (221 bp; lane 9 and 10) DA receptors of BV-2 cells (lane 1, 3, 5, 7 and 9) and
mouse primary microglial cells (lane 2, 4, 6, 8 and 10) is shown. Lane M represents
100-bp DNA ladder marker. Results show representative results of 4 independent
experiments.which are produced in the process of tyrosine oxidation by tyros-
inase, we estimated the effect of tyrosinase in tyrosine-free DMEM
without FBS. In the absence of tyrosinase, the pretreatment with
10 mM DA for 1 h did not affect LPS-induced NO production
(Fig. 4D). On the other hand, in the presence of 300 U/mL tyrosi-
nase, the pretreatment with 10 mM DA for 1 h signiﬁcantly atten-
uated LPS-induced NO production.
Next, we examined the formation of quinoprotein after DA
treatment. Treatment with DA for 24 h concentration-dependently
increased the level of quinoprotein (Fig. 5A), and this increase was
signiﬁcantly inhibited by 10 mM NAC or 500 mM ascorbic acid
(Fig. 5B). In the absence of tyrosinase, the pretreatment with 10 mM
DA for 1 h did not affect the level of quinoprotein (Fig. 5C). On the
other hand, in the presence of 300 U/mL tyrosinase, treatment with
10 mM DA for 1 h signiﬁcantly increased the level of quinoprotein.
3.4. DA attenuated NO production induced by the combination of
IFN-g and TNF-a in BV-2 cells
As it has been reported that cytokines such as IFN-g and TNF-a
induce NO production in microglial cells (27), we examined the
effect of DA on cytokine-induced NO production in BV-2 cells.
Treatment of the cells with TNF-a concentration-dependently
increased NO production in the presence of 3 U mL1 IFN-g but
not in the absence of it (Fig. 6A). Pretreatment with DA for 24 h
Y. Yoshioka et al. / Journal of Pharmacological Sciences 130 (2016) 51e59 55attenuated the NO production induced by the combination of 10 ng
mL1 TNF-a and 3 U mL1 IFN-g in a concentration-dependent
manner (Fig. 6B), and this attenuation was negated by 10 mM
NAC (Fig. 6C).
3.5. DA attenuated LPS-induced NO production in mouse primary
microglial cells
We examined the effect of DA on LPS-induced NO production by
mouse microglial cells in primary culture. Pretreatment of the cells
with DA for 24 h attenuated the LPS-induced NO production in a
concentration-dependent manner (Fig. 7A). DA at a concentration
up to 100 mM did not have any cytotoxicity towards the mouse
primary microglial cells (data not shown). The attenuation of LPS-
induced NO production by pretreatment with 10 mM DA was
partially inhibited by 10 mM sulpiride, but not by 10 mM SCH-23390
(Fig. 7B). Also, the LPS-induced NO production was signiﬁcantly
attenuated by pretreatment with 10 mM bromoctiptine, but not
with 10 mM CY208-243 (Fig. 7C). The attenuation of LPS-induced
NO production by pretreatment with 10 mM DA was partially, but
signiﬁcantly, inhibited by 10 mM NAC (Fig. 7D).
4. Discussion
Activated microglia secrete an excess amount of NO, which has
been implicated in the induction of neuronal damage in certain
types of brain injury. Therefore, the regulation of NO production by
microglial cells is important for the maintenance of brain homeo-
stasis and is vital for neuronal survival following brain injury.
It has been reported that many physiological actions of DA are
mainly mediated by its receptors (14). In the present study, neither
SCH-23390 nor sulpiride, D1-like and D2-like receptor antagonists,
respectively, affected the attenuation of LPS-induced NO produc-
tion by DA in BV-2 cells (Fig. 3A). In addition, pretreatment with
neither CY 208-243 nor bromocriptine, D1-like and D2-like receptor
agonists, respectively, inhibited this production (Fig. 3B). These
results indicate that DA inhibited the LPS-induced NO production
independently of DA receptors in BV-2 cells. It was reported that DA
attenuated LPS-induced NO production through both D1-like and
D2-like receptors in mouse and rat microglial cells in primary cul-
ture (28). In this study, in mouse primary microglial cells, the LPS-
induced NO production was signiﬁcantly attenuated by bro-
moctiptine, and the attenuation of LPS-induced NO production by
pretreatment with DA was partially inhibited by sulpiride (Fig. 7B
and C). In addition, although NAC nearly completely inhibited the
effect of DA in BV-2 cells (Fig. 4A), NAC partially inhibited its effect
in mouse microglial cells in primary culture (Fig. 7D). Therefore, DA
may have attenuated LPS-induced NO production by microglial
cells through both DA receptor-dependent and -independentFig. 4. DA attenuated LPS-induced NO production through the formation of DAQ in BV-
2 cells. (A) BV-2 cells were treated for 24 h with 10 mM DA in the absence or presence
of 10 mM NAC or 500 mM ascorbic acid (AA). Then the cells were treated with
0.1 mg mL1 LPS for 24 h. The nitrite levels were determined by performing the Griess
assay. Results show the mean ± s.e. obtained from 4 independent experiments.
**P < 0.01, signiﬁcant difference between bracketed values (Dunnett's test). (B, C) BV-
2 cells were treated with 50 mM HX alone or in combination with it and XO (B) or with
hydrogen peroxide (C) at the indicated concentrations for 24 h. Then the cells were
treated with 0.1 mg mL1 LPS for 24 h. The nitrite levels were determined by per-
forming the Griess assay. Results show the mean ± s.e. obtained from 3 independent
experiments. (D) BV-2 cells were treated for 1 h with 10 mM DA in the absence or
presence of 300 U mL1 tyrosinase in tyrosine-free DMEM without serum. Then the
cells were treated with 0.1 mg mL1 LPS in FBS/DMEM for 24 h. The nitrite levels were
determined by performing the Griess assay. Results show the mean ± s.e. obtained
from 4 independent experiments. **P < 0.01, signiﬁcantly different from values without
DA pretreatment (Sheffe's test).
Fig. 5. Effects of NAC and ascorbic acid on DA-induced increase in the level of quino-
protein in BV-2 cells. (A) BV-2 cells were treatedwith DA at the indicated concentrations
for 24 h. Then the quinoprotein level was determined by performing the NBT/glycinate
assay. The quinoprotein level was expressed as percentage increase over that in the
untreated control. Results show the mean ± s.e. obtained from 4 independent experi-
ments. *P < 0.05, **P < 0.01, signiﬁcantly different from DA-untreated control (Sheffe's
test). (B) BV-2 cells were treated for 24 h with 10 mM DA in the absence or presence of
10 mM NAC or 500 mM ascorbic acid (AA). Then the quinoprotein level was determined
by performing the NBT/glycinate assay. The quinoprotein level was expressed as per-
centage increase over that in the untreated control. Results show the mean ± s.e. ob-
tained from 4 independent experiments. **P < 0.01, signiﬁcant difference between
bracketed values (Dunnett's test). (C) BV-2 cellswere treated for 1 hwith 10 mMDA in the
absence or presence of 300 U mL1 tyrosinase in tyrosine-free DMEM without serum.
The quinoprotein level was expressed as percentage increase over that in the untreated
control. Results show the mean ± s.e. obtained from 4 independent experiments.
**P < 0.01, signiﬁcantly different from the untreated control (Sheffe's test).
Fig. 6. DA attenuated NO production induced by the combination of IFN-g and TNF-a
in BV-2 cells. (A) BV-2 cells were treated for 24 h with TNF-a at the indicated con-
centrations in the absence (open circle) or presence (closed circle) of 3 U mL1 IFN-g.
The nitrite levels were determined by performing the Griess assay. Results show the
mean ± s.e. obtained from 3 independent experiments. (B) BV-2 cells were treated
with DA at the indicated concentrations for 24 h. Then the cells were treated with a
combination of 3 U mL1 IFN-g and 10 ng mL1 TNF-a for 24 h. The nitrite levels were
determined by performing the Griess assay. Results show the mean ± s.e. obtained
from 4 independent experiments. **P < 0.01, signiﬁcantly different from 3 U mL1 IFN-
g and 10 ng mL1 TNF-a (Sheffe's test). (C) BV-2 cells were treated for 24 h with 30 mM
DA in the absence or presence of 10 mM NAC. Then the cells were treated with
0.1 mg mL1 LPS for 24 h. The nitrite levels were determined by performing the Griess
assay. Results show the mean ± s.e. obtained from 4 independent experiments.
**P < 0.01, signiﬁcant difference between bracketed values (Dunnett's test).
Y. Yoshioka et al. / Journal of Pharmacological Sciences 130 (2016) 51e5956mechanisms. In this study, although we could not ﬁnd differences
in mRNA expression of D2-like DA receptor subtypes between
mouse primary microglial cells and BV-2 cells (Fig. 2), the LPS-
induced NO production was signiﬁcantly attenuated by
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BV-2 cells (Fig. 3B). This discrepancymay be due to the difference in
the magnitude or the pathways of postreceptor signaling after D2
receptor stimulation in each cell. Further studies are needed to
reveal this discrepancy concerning DA receptor-mediated action of
DA on NO production.
It is well known that DA oxidation generates ROS such as
hydrogen peroxide and superoxide anion (15). It was earlier
demonstrated that hydrogen peroxide inhibits IL-1-induced NO
production in rat mesangial cells (29) and that superoxide anion
generated by autoxidation of L-dopa inhibits LPS/INF-g-induced NO
production in rat C6 glioma cells (32). In the present study, pre-
treatment with hydrogen peroxide or superoxide anion did not
affect the LPS-induced NO production (Fig. 4B and C). The differ-
ences between these reports and our study may be explained by
the difference in cell types. It has been reported that DA readily
oxidized to DAQ (16), and it is well known that DAQ can modify
cysteine residues of proteins, resulting in the formation of quino-
proteins (16, 19, 30). It has been also reported that the free-radical
scavengers NAC and ascorbic acid inhibit DA oxidation (31). In the
present study, anti-oxidants NAC and ascorbic acid inhibited the
attenuation of LPS-induced NO production by DA in BV-2 cells
(Fig. 4A). In addition, DA concentration-dependently increased the
quinoprotein level, and this increase was signiﬁcantly inhibited by
both NAC and ascorbic acid in BV-2 cells (Fig. 5A and B). Further-
more, tyrosinase accelerated the inhibitory effect of DA on LPS-
induced NO production (Fig. 4D). These results suggest that DAQ
generated by DA oxidation attenuated LPS-induced NO production
in BV-2 cells.
It has been reported that DAQ conjugates with cysteine residues
of several proteins such as tyrosine hydroxylase and tryptophan
hydroxylase, and consequently inhibits their functions (17, 26). In
the present study, DA increased the quinoprotein level (Fig. 5A) and
decreased the LPS-induced expression of iNOS mRNA (Fig. 1D).
These observations suggest that DAQ generated by the oxidation of
DA modiﬁed cysteine residues of a certain protein that contributed
to LPS-induced iNOS expression and thereby inhibited its function,
resulting in the attenuation of LPS-induced NO production in BV-
2 cells. As to the nature of such a protein, it has been reported that
c-Jun N-terminal kinase (JNK), one of the 3 members of the
mitogen-activated protein kinase family, plays an important role in
TNF-a-induced iNOS induction and NO production in mouse mac-
rophages (33, 34). We also previously reported that a selective JNK
inhibitor attenuated LPS-induced iNOS expression and NO pro-
duction in BV-2 cells (24). In addition, it was previously reportedFig. 7. DA attenuated LPS-induced NO production in mouse microglial cells in primary
culture. (A) Primary cultures of mouse microglial cells were treated with DA at the
indicated concentrations for 24 h. Then the cells were treated with 0.1 mg mL1 LPS for
24 h. The nitrite levels were determined by performing the Griess assay. Results show
the mean ± s.e. obtained from 4 independent experiments. **P < 0.01, signiﬁcantly
different from values without DA pretreatment (Sheffe's test). (B) Mouse microglial
cells in primary culture were treated for 24 h with 10 mM DA in the absence or pres-
ence of 10 mM SCH-23390 or 10 mM sulpiride. Then the cells were treated with
0.1 mg mL1 LPS for 24 h. The nitrite levels were determined by performing the Griess
assay. Results show the mean ± s.e. obtained from 3 independent experiments.
*P < 0.05, **P < 0.01, signiﬁcant difference between bracketed values (Dunnett's test).
(C) Mouse microglial cells in primary culture were treated with 10 mM CY 208-243 or
10 mM bromocriptine for 24 h. Then the cells were treated with 0.1 mg mL1 LPS for
24 h. The nitrite levels were determined by performing the Griess assay. Results show
the mean ± s.e. obtained from 3 independent experiments. **P < 0.01, signiﬁcantly
different from values for LPS alone (Sheffe's test). (D) Mouse microglial cells in primary
culture were treated for 24 h with 10 mM DA in the absence or presence of 10 mM NAC.
Then the cells were treated with 0.1 mg mL1 LPS for 24 h. The nitrite levels were
determined by performing the Griess assay. Results show the mean ± s.e. obtained
from 4 independent experiments. **P < 0.01, signiﬁcant difference between bracketed
values (Dunnett's test).
Y. Yoshioka et al. / Journal of Pharmacological Sciences 130 (2016) 51e5958that JNK has a conserved cysteine residue in its ATP-binding site
and that the covalent binding of its residue by the selective inhib-
itor JNKeINe8 inhibits the phosphorylation of c-Jun, a direct sub-
strate of JNK (35). These observations suggest that DAQ generated
by the oxidation of DA could inhibit JNK activity by modifying the
cysteine residue in its ATP-binding site. Further studies are required
to reveal the exact mechanism of DAQ-induced attenuation of NO
production.
DA is chemically unstable and undergoes auto-oxidation to
form DAQ and superoxide anion (15). This superoxide anion re-
acts rapidly with NO to produce peroxynitrite, which is a highly
reactive free radical and mediates the toxicity of NO and the
superoxide anion (36). Thus, the inhibition of NO production by
DAQ might be important to protect the surrounding neuronal
and glial cells from the toxicity of peroxynitrite. The over-
production of NO by activated microglial cells has been shown to
induce neuronal injury in some models of neurodegenerative
disorders and brain injury (11e13, 37, 38). In our study, DA
attenuated not only LPS-stimulated but also IFN-g and TNF-a-
stimulated NO production in BV-2 cells (Fig. 1B and 6B), sug-
gesting that DAQ would afford neuroprotection by inhibiting NO
production by activated microglial cells. On the other hand, DAQ
causes the death of some types of neuronal cells (39e41). Alto-
gether, the effect of DAQ on neuronal survival could be both
beneﬁcial and detrimental, depending on the amount and the
site of formation.
In conclusion, our results demonstrate that DA attenuated the
NO production by LPS-stimulated microglial cells by reducing the
induction of iNOS and that this reduced production was possibly
mediated through the formation of DAQ.Conﬂicts of interest
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